Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Huub-Jan Kleijn"'
Autor:
Dhananjay D. Marathe, Petra M. Jauslin, Huub Jan Kleijn, Carolina deMiranda Silva, Anne Chain, Thomas Bateman, Peter M. Shaw, Anson K. Abraham, Eunkyung A. Kauh, Yanfang Liu, Rodolfo F. Perini, Dinesh P. deAlwis, Lokesh Jain
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 10, Pp 1499-1510 (2023)
Abstract Belzutifan (Welireg, Merck & Co., Inc., Rahway, NJ, USA) is an oral, potent inhibitor of hypoxia‐inducible factor 2α, approved for the treatment of certain patients with von Hippel–Lindau (VHL) disease‐associated renal cell carcinoma
Externí odkaz:
https://doaj.org/article/9fb57ee9c9224d38a940c36af9575776
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 8, Pp 1080-1092 (2023)
Abstract Sparsentan is a single‐molecule dual endothelin angiotensin receptor antagonist (DEARA) currently under investigation as a treatment for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). A population pharmacokinetic (PK
Externí odkaz:
https://doaj.org/article/fa24d3487437408fb452433fbd197e18
Autor:
Xuemin Jiang, Russ Wada, Bill Poland, Huub Jan Kleijn, Bin Fan, Guowen Liu, Hua Liu, Stephanie Kapsalis, Hua Yang, Kha Le
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 3, Pp 942-953 (2021)
Abstract Ivosidenib is a once daily (q.d.), orally available, potent mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor approved for treatment of patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and intensive chemotherapy inel
Externí odkaz:
https://doaj.org/article/8ac7c80e9ae94ab88f41b9cf14066d9b
Autor:
Chi‐Chung Li, Tiffini Voss, Ken Kowalski, Bei Yang, Huub Jan Kleijn, Christopher J. Jones, Rolien Bosch, David Michelson, Matthew DeAngelis, Yang Xu, Iris Xie, Prajakti A. Kothare
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 3, Pp 482-490 (2020)
Ubrogepant (MK‐1602) is a novel, oral, calcitonin gene‐related peptide receptor antagonist in clinical development with positive phase III outcomes for acute treatment of migraine. This paper describes the population exposure‐response (E‐R) m
Externí odkaz:
https://doaj.org/article/eb872eb56df648a2b8a35bd1a4180f5a
Publikováno v:
Frontiers in Neurology, Vol 12 (2021)
Objective: To investigate the pharmacokinetics, pharmacodynamics, and exposure–response of the approved 900/1,200 mg dosing regimen for the terminal complement component 5 (C5) inhibitor eculizumab in patients with generalized myasthenia gravis (gM
Externí odkaz:
https://doaj.org/article/a4769ce0c1ae43f096e7ccb380048d98
Publikováno v:
Frontiers in Neurology, Vol 12 (2021)
Objective: To investigate the pharmacokinetics and pharmacodynamics of the approved 900/1,200 mg dosing regimen for the terminal complement component 5 (C5) inhibitor eculizumab in patients with neuromyelitis optica spectrum disorder (NMOSD).Methods:
Externí odkaz:
https://doaj.org/article/5bf3d34033c44dfba1ce9a5be046bb5c
Publikováno v:
Clinical Therapeutics. 45:356-362
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0cbfa58ad1c83e73dcce82058a4b2f6
https://doi.org/10.1016/j.clinthera.2023.02.006
https://doi.org/10.1016/j.clinthera.2023.02.006
Autor:
David R. Muccino, Alyn H. Morice, Surinder S. Birring, Peter V. Dicpinigaitis, Ian D. Pavord, Christopher Assaid, Huub Jan Kleijn, Azher Hussain, Carmen La Rosa, Lorcan McGarvey, Jaclyn A. Smith
Publikováno v:
ERJ Open Research, Vol 6, Iss 4 (2020)
Background We present study designs, dose selection and preliminary patient characteristics from two phase 3 clinical trials of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough (RCC) or unexplained chronic cough (UCC). Methods COUG
Externí odkaz:
https://doaj.org/article/797aecd766a64455a4cd9c812cd2c339
Autor:
Russ Wada, Stephanie M. Kapsalis, Bill Poland, Xuemin Jiang, Guowen Liu, Bin Fan, Huub Jan Kleijn, Hua Liu, Kha Le, Hua Yang
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 3, Pp 942-953 (2021)
Clinical and Translational Science, Vol 14, Iss 3, Pp 942-953 (2021)
Ivosidenib is a once daily (q.d.), orally available, potent mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor approved for treatment of patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and intensive chemotherapy ineligible AM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47d81c9c6bb18874780e88db514c6ba9
http://europepmc.org/articles/PMC8212730
http://europepmc.org/articles/PMC8212730
Autor:
Bei Yang, Prajakti A. Kothare, Tiffini Voss, Iris Xie, Chi-Chung Li, Yang Xu, Matthew DeAngelis, David Michelson, Ken Kowalski, Christopher Jones, Rolien Bosch, Huub Jan Kleijn
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 3, Pp 482-490 (2020)
Clinical and Translational Science
Clinical and Translational Science
Ubrogepant (MK‐1602) is a novel, oral, calcitonin gene‐related peptide receptor antagonist in clinical development with positive phase III outcomes for acute treatment of migraine. This paper describes the population exposure‐response (E‐R) m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99423d5b7c0b41783b3e3eef16d90ef9
https://doaj.org/article/eb872eb56df648a2b8a35bd1a4180f5a
https://doaj.org/article/eb872eb56df648a2b8a35bd1a4180f5a